BioSpace News Archive

Aileron Therapeutics, a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, announced that it will effect a 1-for-20 reverse stock split of its common stock.

SOTIO Biotech presented preclinical dataevaluating the mechanism of action and metabolic function of its BOXR T cell platform in a poster presentation at the Society for Immunotherapy of Cancer 37th Annual Meeting, taking place in Boston, Massachusetts from November 8-12, 2022.

ProPhase Labs, Inc., a growth oriented and diversified diagnostics, genomics and biotech company, reported its financial and operational results for the third quarter ended September 30, 2022.

Vyant Bio, Inc. is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Lipidio Pharmaceuticals Inc., a biopharmaceutical company developing novel therapeutics for dermatological and metabolic diseases, announced the close of an extension to its Series A financing, bringing the total amount raised to over $20M.

KaliVir Immunotherapeutics, Inc. announced the presentation of data on its lead pre-clinical candidate VET3-TGI presented in a poster session at the 37th Annual Meeting of the Society for Immunology of Cancer in Boston, Massachusetts.

Alpheus™ Medical, Inc, a privately held company developing a novel sonodynamic therapy (SDT) platform targeting solid body cancers, today announced the treatment of the first three patients in the U.S.-based multi-center Phase 1 clinical trial evaluating the safety and optimal dosage of the company’s proprietary platform.

Wugen, Inc. today announced that management will present at 9:45 a.m. GMT (4:45 a.m. ET) on Thursday, November 17, 2022 at the upcoming Jefferies London Healthcare Conference.

TAE Life Sciences announced a partnership with HDX Corporation to bring TLS’s targeted radiation therapy to South Korea for the treatment of difficult-to-treat cancers, such as brain, head and neck cancers and melanoma.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today reported its financial results for the quarter ended September 30, 2022.